These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17721579)

  • 1. PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision.
    Isaacs RJ; Frampton CM; Kuper-Hommel MJ
    N Z Med J; 2007 Aug; 120(1259):U2676. PubMed ID: 17721579
    [No Abstract]   [Full Text] [Related]  

  • 2. PHARMAC responds on Herceptin assumptions and decisions.
    Metcalfe S; Evans J
    N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504
    [No Abstract]   [Full Text] [Related]  

  • 3. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
    Rosevear M
    N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hype over herceptin.
    Fitzpatrick J
    Nurs N Z; 2009 Mar; 15(2):4-5. PubMed ID: 19554708
    [No Abstract]   [Full Text] [Related]  

  • 5. Skipping for herceptin funds.
    Harrison J
    Nurs N Z; 2007 Nov; 13(10):4. PubMed ID: 18084962
    [No Abstract]   [Full Text] [Related]  

  • 6. Raising money for herceptin.
    Harrison J
    Nurs N Z; 2007 Mar; 13(2):3. PubMed ID: 17429882
    [No Abstract]   [Full Text] [Related]  

  • 7. Roche responds to the 'Herceptin or deception' article.
    Petersen S
    N Z Med J; 2006 Jul; 119(1237):U2069; author reply U2069. PubMed ID: 16862210
    [No Abstract]   [Full Text] [Related]  

  • 8. Herceptin, Pharmac and the New Zealand District Health Boards: keeping abreast of the Code of Health and Disability Services Consumers' Rights?
    Graham K
    J Law Med; 2008 Aug; 16(1):103-8. PubMed ID: 18807798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

  • 10. How much will Herceptin really cost? The money is already there.
    Minhas R
    BMJ; 2006 Dec; 333(7580):1219; discussion 1219-20. PubMed ID: 17158392
    [No Abstract]   [Full Text] [Related]  

  • 11. How much will Herceptin really cost? Balancing local and national priorities is not new.
    Dillon A; Littlejohns P
    BMJ; 2006 Dec; 333(7580):1219; discussion 1219-20. PubMed ID: 17158393
    [No Abstract]   [Full Text] [Related]  

  • 12. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 13. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant trastuzumab for breast cancer: editorial does not mention health economics of drug.
    McLaren EH
    BMJ; 2005 Nov; 331(7526):1203. PubMed ID: 16293854
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant trastuzumab for breast cancer: an increasingly common ethical and economic conundrum.
    Grove ML
    BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293847
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article.
    ; Burgess EP
    N Z Med J; 2006 Jul; 119(1237):U2065; author reply U2065. PubMed ID: 16862207
    [No Abstract]   [Full Text] [Related]  

  • 18. The debate about the funding of Herceptin: a case study of 'countervailing powers'.
    Gabe J; Chamberlain K; Norris P; Dew K; Madden H; Hodgetts D
    Soc Sci Med; 2012 Dec; 75(12):2353-61. PubMed ID: 23036988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genentech caps cost of cancer drug for some patients.
    Pollack A
    N Y Times Web; 2006 Oct; ():C2. PubMed ID: 17061339
    [No Abstract]   [Full Text] [Related]  

  • 20. Making a case for a $2700-a-month drug.
    Sibbald B
    CMAJ; 1999 Nov; 161(9):1173. PubMed ID: 10569111
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.